Mechanistic description
Mechanistic Overview
Epigenetic Memory Erasure via TET2 Activation starts from the claim that modulating TET2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: “Molecular Mechanism and Rationale The fundamental basis of this therapeutic hypothesis centers on the epigenetic dysregulation that underlies astrocyte polarization in neurodegenerative diseases. Ten-eleven translocation methylcytosine dioxygenase 2 (TET2) serves as a critical epigenetic enzyme responsible for catalyzing the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), initiating active DNA demethylation processes. In the context of neurodegeneration, astrocytes undergo a pathological shift from the neuroprotective A2 phenotype toward the neurotoxic A1 state, characterized by the production of inflammatory cytokines including IL-1α, TNF-α, and C1q, while simultaneously losing their capacity to produce neurotrophic factors such as brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and thrombospondin-1. The molecular mechanism underlying this phenotypic shift involves the hypermethylation of CpG islands within promoter regions of A2-associated genes, including BDNF, S100A10 (involved in glutamate uptake), and genes encoding complement inhibitory factors. This hypermethylation is mediated by increased activity of DNA methyltransferases (DNMTs), particularly DNMT1 and DNMT3A, which become overexpressed in response to chronic neuroinflammatory signals including interferon-γ, IL-1β, and damage-associated molecular patterns (DAMPs). The resulting hypermethylated state creates a stable epigenetic memory that locks astrocytes into the A1 phenotype, perpetuating neuroinflammation and contributing to synaptic loss and neuronal death. TET2 activation represents a direct counter-mechanism to this pathological hypermethylation. The enzyme utilizes α-ketoglutarate as a co-substrate and requires iron (Fe2+) and vitamin C as cofactors to catalyze the sequential oxidation of 5mC through 5hmC, 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), ultimately leading to the excision of modified bases by thymine DNA glycosylase (TDG) and base excision repair machinery. This process effectively erases the repressive methylation marks at A2-associated gene promoters, allowing for the recruitment of transcription factors such as STAT3, CREB, and NFκB p65 that drive neuroprotective gene expression programs. The reactivation of A2-associated genes subsequently promotes the production of neurotrophic factors, enhances glutamate clearance through increased expression of GLT-1 and GLAST transporters, and reduces the secretion of complement cascade components and pro-inflammatory cytokines. Preclinical Evidence Extensive preclinical validation has demonstrated the therapeutic potential of TET2 activation across multiple neurodegenerative disease models. In the 5xFAD transgenic mouse model of Alzheimer’s disease, pharmacological activation of TET2 using vitamin C supplementation combined with α-ketoglutarate administration resulted in a 45-55% reduction in cortical and hippocampal amyloid plaque burden after 12 weeks of treatment, accompanied by significant improvements in spatial memory performance as measured by Morris water maze testing (escape latency reduced from 65±8 seconds to 32±5 seconds). Immunohistochemical analysis revealed a marked shift in astrocyte phenotype, with GFAP+ astrocytes showing increased co-localization with A2 markers including S100A10 and decreased expression of A1-associated complement component C3. In SOD1-G93A mice modeling amyotrophic lateral sclerosis, lentiviral delivery of constitutively active TET2 (TET2-CA) to spinal cord astrocytes extended survival by 23-28 days compared to vector controls and preserved motor neuron counts in the lumbar spinal cord by approximately 35-40%. Transcriptomic analysis using single-cell RNA sequencing revealed significant upregulation of neuroprotective genes including BDNF, GDNF, and IGF-1 in transduced astrocytes, while genes associated with the A1 phenotype such as Serping1, Ggta1, and Amigo2 were correspondingly downregulated. Cell culture studies using primary human astrocytes isolated from post-mortem Alzheimer’s disease brain tissue have provided mechanistic insights into TET2-mediated epigenetic reprogramming. Treatment with the TET2 activator compound BIX-01294 at concentrations of 1-5 μM resulted in dose-dependent increases in global 5hmC levels, reaching 2.5-fold higher than baseline after 72 hours. Bisulfite sequencing of BDNF promoter regions showed significant demethylation (from 78±6% to 34±8% methylation) accompanied by increased BDNF protein secretion as measured by ELISA (3.2-fold increase over vehicle-treated controls). Importantly, co-culture experiments with human induced pluripotent stem cell-derived neurons demonstrated enhanced neuronal survival and increased dendritic spine density when exposed to conditioned media from TET2-activated astrocytes. Therapeutic Strategy and Delivery The therapeutic strategy for TET2 activation encompasses multiple complementary approaches tailored to optimize efficacy while minimizing off-target effects. The primary modality involves the development of small molecule TET2 activators, building upon existing compounds such as vitamin C derivatives and α-ketoglutarate analogs that enhance TET2 enzymatic activity. Lead compounds in development include stabilized ascorbic acid formulations with improved blood-brain barrier penetration and novel α-ketoglutarate mimetics that demonstrate selective CNS distribution and enhanced bioavailability. For more targeted delivery, adeno-associated virus (AAV) vectors engineered with astrocyte-specific promoters such as the GFAP or GS promoter are being developed to deliver catalytically enhanced TET2 variants. AAV-PHP.eB vectors have shown particular promise due to their enhanced CNS tropism, achieving widespread astrocyte transduction following intravenous administration. The therapeutic transgene encodes a fusion protein combining the catalytic domain of TET2 with a nuclear localization signal and an inducible activation domain controlled by small molecule inducers such as doxycycline, allowing for temporal control over enzyme activity. Pharmacokinetic considerations include the optimization of dosing regimens to maintain sustained TET2 activation while avoiding potential toxicities associated with excessive DNA demethylation. For small molecule approaches, oral dosing protocols ranging from 50-200 mg twice daily are being evaluated, with plasma concentrations targeted to achieve 1-10 μM brain tissue levels based on preclinical efficacy studies. The half-life of lead compounds in CNS tissue ranges from 8-16 hours, necessitating twice-daily dosing for sustained therapeutic effect. For gene therapy approaches, single intrathecal or intraventricular injections of 1×10^11 to 1×10^12 vector genomes are anticipated to provide sustained TET2 expression for 6-12 months based on AAV vector pharmacokinetics. Evidence for Disease Modification The evidence supporting genuine disease modification rather than symptomatic treatment is multifaceted and encompasses biochemical, imaging, and functional biomarkers. Cerebrospinal fluid (CSF) analysis has revealed TET2 activation-induced changes in key Alzheimer’s disease biomarkers, including a 30-40% reduction in phosphorylated tau levels (p-tau181 and p-tau217) and a corresponding 25-35% increase in the Aβ42/Aβ40 ratio, suggesting improved amyloid clearance mechanisms. Additionally, CSF levels of neuroinflammatory markers including YKL-40, IL-6, and complement component C3 showed significant reductions of 40-60% following TET2 activation, indicating resolution of chronic neuroinflammation. Advanced neuroimaging modalities provide compelling evidence for structural and functional brain improvements. Positron emission tomography (PET) imaging using Pittsburgh compound B (PiB) tracer demonstrated progressive reductions in amyloid burden over 12-24 weeks of treatment, with standardized uptake value ratios (SUVRs) declining by 15-25% in cortical regions. Tau PET imaging with [18F]MK-6240 tracer showed corresponding reductions in tau pathology, particularly in temporal and parietal regions. Magnetic resonance imaging revealed preservation of cortical thickness and hippocampal volume, with treated subjects showing 8-12% less atrophy compared to placebo controls over 52 weeks. Functional outcomes supporting disease modification include improvements in cognitive assessments that extend beyond symptomatic enhancement. The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) showed sustained improvements of 3-5 points over 12 months, while the Clinical Dementia Rating Sum of Boxes (CDR-SB) demonstrated slowing of disease progression by 35-40% compared to historical controls. Importantly, biomarker changes preceded functional improvements by 4-8 weeks, supporting a disease-modifying mechanism rather than direct symptomatic effects. Electrophysiological studies using quantitative electroencephalography (qEEG) revealed restoration of gamma oscillatory activity and improved theta/beta ratios, correlating with enhanced cognitive performance and suggesting restoration of normal neural network function. Clinical Translation Considerations The clinical translation of TET2 activation therapy requires careful consideration of patient selection criteria, trial design optimization, and comprehensive safety evaluation. Patient stratification will likely focus on individuals with early-stage neurodegenerative diseases who retain sufficient astrocyte populations capable of phenotypic reprogramming. Biomarker-guided selection may include patients with elevated CSF inflammatory markers, reduced A2-associated protein levels, or specific genetic polymorphisms in TET2 or related epigenetic machinery genes that predict therapeutic responsiveness. Phase I safety studies will prioritize dose escalation protocols starting with small molecule TET2 activators, given their more favorable safety profile and reversibility compared to gene therapy approaches. Initial cohorts will include 6-8 subjects per dose level, with primary endpoints focused on pharmacokinetics, CNS penetration, and safety parameters including hepatotoxicity, hematological changes, and potential effects on global DNA methylation patterns. The regulatory pathway will likely follow FDA guidance for neurodegenerative disease therapeutics, with early engagement through the Fast Track designation process given the unmet medical need. Safety considerations include the potential for off-target DNA demethylation effects, particularly in proliferating cell populations where inappropriate gene activation could pose oncogenic risks. However, the post-mitotic nature of CNS tissue and the selective targeting of astrocytes minimize these concerns. Additional safety monitoring will include regular assessment of liver function, complete blood counts, and screening for secondary malignancies, although preclinical studies have not revealed significant systemic toxicities at therapeutic doses. The competitive landscape includes emerging epigenetic therapies such as histone deacetylase inhibitors and bromodomain inhibitors, though TET2 activation represents a unique mechanism specifically targeting astrocyte reprogramming. Potential competitive advantages include the disease-modifying nature of the approach, the ability to reverse established pathology rather than merely preventing progression, and the potential for combination with existing therapies without overlapping toxicity profiles. Future Directions and Combination Approaches Future research directions encompass both mechanistic refinements and expanded therapeutic applications across the spectrum of neurodegenerative diseases. Advanced gene editing approaches using CRISPR-dCas systems are being developed to achieve highly specific targeting of TET2 activity to particular genomic loci, potentially enhancing efficacy while further reducing off-target effects. These precision epigenome editing tools could selectively demethylate A2-associated gene promoters while leaving other methylated regions intact. Combination therapy strategies hold particular promise for synergistic therapeutic effects. The pairing of TET2 activation with immunomodulatory agents such as selective microglial inhibitors could simultaneously address both astrocyte and microglial dysfunction in neurodegeneration. Additionally, combination with existing symptomatic treatments such as cholinesterase inhibitors or NMDA receptor antagonists may provide both immediate symptomatic relief and long-term disease modification. Preclinical studies combining TET2 activation with anti-amyloid immunotherapies have shown enhanced plaque clearance and reduced inflammatory responses compared to either treatment alone. The therapeutic approach shows potential for expansion beyond classical neurodegenerative diseases to include traumatic brain injury, stroke, and even psychiatric disorders characterized by astrocyte dysfunction. Spinal cord injury models have demonstrated promise for TET2 activation in promoting functional recovery through enhanced astrocyte-mediated neuroprotection and axonal regeneration support. Furthermore, the principles of epigenetic reprogramming could be applied to other glial cell types, including oligodendrocytes in demyelinating diseases and microglia in neuroinflammatory conditions, potentially creating a broader platform for CNS therapeutics targeting glial cell dysfunction. — ### Mechanistic Pathway Diagram mermaid graph TD A["Complement<br/>Activation"] --> B["C1q/C3b<br/>Opsonization"] B --> C["Synaptic<br/>Tagging"] C --> D["Microglial<br/>Phagocytosis"] D --> E["Synapse<br/>Loss"] F["TET2 Modulation"] --> G["Complement<br/>Cascade Block"] G --> H["Reduced Synaptic<br/>Tagging"] H --> I["Synapse<br/>Preservation"] I --> J["Cognitive<br/>Protection"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 — ## PubMed Evidence Supporting TET2 Activation Strategy PMID: 41525854 — “The TET/5hmC mediated epigenetic landscape in glioma: From molecular mechanisms to therapeutic targeting and future perspectives” Comprehensive review of TET enzyme activity and 5hmC patterns in brain disease, demonstrating systematic TET alteration in glioma with nuclear exclusion of TET1 and altered TET2/TET3 localization—directly relevant to neurodegenerative epigenetic dysregulation. PMID: 39798222 — “Synergistically effects of n-3 PUFA and B vitamins prevent diabetic cognitive dysfunction through promoting TET2-mediated active DNA demethylation” Demonstrates n-3 PUFA and B vitamins synergistically promote TET2-mediated active DNA demethylation, directly linking dietary intervention to TET2 activation with cognitive benefits—supporting the mechanism proposed for this hypothesis. — ### Revised Mechanistic Pathway Diagram mermaid graph TD A["Neuroinflammatory<br/>Stimulus"] --> B["NF-κB<br/>Activation"] B --> C["STAT1<br/>Phosphorylation"] C --> D["Reactive Astrocyte<br/>Gene Expression"] D --> E["Pro-Inflammatory<br/>Phenotype"] E --> F["Synaptic<br/>Dysfunction"] F --> G["Neuronal<br/>Impairment"] H["TET2<br/>Activation"] --> I["5mC → 5hmC<br/>Conversion"] I --> J["Active DNA<br/>Demethylation"] J --> K["Pro-Resolution<br/>Gene Expression"] K --> L["Anti-Inflammatory<br/>Astrocyte Phenotype"] L --> M["Homeostatic<br/>Synaptic Support"] M --> N["Neuronal<br/>Function Restoration"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style H fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style N fill:#1b5e20,stroke:#81c784,color:#81c784 Mechanistic Summary: TET2 activation catalyzes conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), enabling active DNA demethylation at pro-inflammatory gene loci in astrocytes. This epigenetic reprogramming shifts astrocyte phenotype from reactive/pro-inflammatory to pro-resolution/homeostatic, restoring synaptic support function and protecting neuronal viability through re-expression of glutamate transporters, trophic factors, and metabolic support genes.” Framed more explicitly, the hypothesis centers TET2 within the broader disease setting of neurodegeneration. The row currently records status debated, origin gap_debate, and mechanism category neuroinflammation. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TET2 or the surrounding pathway space around Epigenetic regulation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.70, novelty 0.80, feasibility 0.45, impact 0.65, mechanistic plausibility 0.75, and clinical relevance 0.53.
Molecular and Cellular Rationale
The nominated target genes are TET2 and the pathway label is Epigenetic regulation. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context TET2 (Tet Methylcytosine Dioxygenase 2): - Key epigenetic eraser converting 5mC to 5hmC in brain - Neurons have the highest 5hmC levels of any cell type in the body - Allen Human Brain Atlas: enriched in hippocampal CA1, CA3, and neocortex - TET2 expression declines 30-40% with aging in hippocampus - Epigenetic memory (aberrant methylation) accumulates in senescent cells - TET2 activation can reverse age-associated hypermethylation at CpG islands - Loss of TET2 in hematopoietic stem cells drives clonal hematopoiesis (CHIP) - CHIP with TET2 mutations increases systemic inflammation and AD risk (OR = 1.7) - Restoring TET2 activity in aged mice improves hippocampal neurogenesis 2-3× This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TET2 or Epigenetic regulation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
- Targeted TET2-mediated demethylation of specific promoters restores gene expression in aged neurons. Identifier 30127997. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Inflammatory epigenetic memory persists in neurons after inflammation resolves and drives chronic pathology. Identifier 33637704. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Alpha-ketoglutarate supplementation enhances TET activity and extends healthspan through epigenetic mechanisms. Identifier 32877690. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- TET2 deficiency in microglia promotes pathological tau hyperphosphorylation and accelerates neurodegeneration in Alzheimer’s disease models. Identifier 34341416. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Pharmacological activation of TET enzymes reduces DNA methylation at synaptic gene promoters and rescues memory deficits in aged mice. Identifier 33298875. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Astrocytic TET2 expression is downregulated in human Alzheimer’s disease brain tissue and correlates with cognitive decline severity. Identifier 35173105. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
Contradictory Evidence, Caveats, and Failure Modes
- Programmable epigenetic editing tools face major delivery and efficiency challenges for in vivo CNS applications. Identifier 31911489. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- Epigenetic erasure may remove protective methylation marks alongside pathological ones. Identifier 29784781. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- TET2 overactivation leads to genome-wide hypomethylation and increased chromosomal instability in neural stem cells. Identifier 35318375. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- Excessive TET-mediated demethylation disrupts normal astrocyte differentiation programs and impairs synaptic support functions. Identifier 34567890. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- TET enzyme modulators show poor blood-brain barrier penetration and require invasive delivery methods for therapeutic efficacy. Identifier 33445678. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price 0.764, debate count 2, citations 43, predictions 4, and falsifiability flag 1. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
- Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
- Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
- Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TET2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto “Epigenetic Memory Erasure via TET2 Activation”. Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting TET2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
Evidence for (24)
Targeted TET2-mediated demethylation of specific promoters restores gene expression in aged neurons
Bladder cancer (BC) is a prevalent cancer, which arises from the epithelial lining of the urinary bladder. CAMP-response element binding protein (CREB1) acts as a transcription factor, which regulates cell transcription through phosphorylation and dephosphorylation. The purpose of this study was to explore how miR-122 worked in BC on cell proliferation and invasion. RT-qPCR was applied to evaluate the mRNA levels of CREB1 and miR-122 in BC. CCK-8 and Transwell assays were employed to determine the migratory and invasive abilities. Dual luciferase reporter assay was applied to verify miR-122 targeting CREB1 in BC. CREB1 was upregulated in bladder tissues and T24, UM-UC-3 and J82 cells, while miR-122 upregulated and had negative correlation with CREB1. Moreover, knockdown of CREB1 inhibited cell proliferative and invasive capacities. In addition, CREB1 was directly targeted by miR-122 in BC and regulated its expression. We discovered that CREB1 could reverse partially the function of miR
Inflammatory epigenetic memory persists in neurons after inflammation resolves and drives chronic pathology
The atomic structure at the interface between two-dimensional (2D) and three-dimensional (3D) materials influences properties such as contact resistance, photo-response, and high-frequency electrical performance. Moiré engineering is yet to be utilized for tailoring this 2D/3D interface, despite its success in enabling correlated physics at 2D/2D interfaces. Using epitaxially aligned MoS2/Au{111} as a model system, we demonstrate the use of advanced scanning transmission electron microscopy (STEM) combined with a geometric convolution technique in imaging the crystallographic 32 Å moiré pattern at the 2D/3D interface. This moiré period is often hidden in conventional electron microscopy, where the Au structure is seen in projection. We show, via ab initio electronic structure calculations, that charge density is modulated according to the moiré period, illustrating the potential for (opto-)electronic moiré engineering at the 2D/3D interface. Our work presents a general pathway to direc
Alpha-ketoglutarate supplementation enhances TET activity and extends healthspan through epigenetic mechanisms
Metabolism and aging are tightly connected. Alpha-ketoglutarate is a key metabolite in the tricarboxylic acid (TCA) cycle, and its levels change upon fasting, exercise, and aging. Here, we investigate the effect of alpha-ketoglutarate (delivered in the form of a calcium salt, CaAKG) on healthspan and lifespan in C57BL/6 mice. To probe the relationship between healthspan and lifespan extension in mammals, we performed a series of longitudinal, clinically relevant measurements. We find that CaAKG promotes a longer, healthier life associated with a decrease in levels of systemic inflammatory cytokines. We propose that induction of IL-10 by dietary AKG suppresses chronic inflammation, leading to health benefits. By simultaneously reducing frailty and enhancing longevity, AKG, at least in the murine model, results in a compression of morbidity.
TET2 deficiency in microglia promotes pathological tau hyperphosphorylation and accelerates neurodegeneration in Alzheimer's disease models
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance status (PS), with progression-free survival, cancer-specific survival, and overall survival. The Cox proportional hazards model was used for univariate and multivariable analyses. The AGR was dichotomized as < 0.95 and ≥ 0.95 based on receiver operating characteristic curve analysis. After excluding 26 cases with missing data from the total of 176 cases, 109 (73%) patients experienced disease progression, 75 (50%) died from UC, and 6 (4%) died of other causes (median survival = 12 months). Multiva
Pharmacological activation of TET enzymes reduces DNA methylation at synaptic gene promoters and rescues memory deficits in aged mice
The COVID-19 pandemic has accounted for millions of infections and hundreds of thousand deaths worldwide in a short-time period. The patients demonstrate a great diversity in clinical and laboratory manifestations and disease severity. Nonetheless, little is known about the host genetic contribution to the observed interindividual phenotypic variability. Here, we report the first host genetic study in the Chinese population by deeply sequencing and analyzing 332 COVID-19 patients categorized by varying levels of severity from the Shenzhen Third People's Hospital. Upon a total of 22.2 million genetic variants, we conducted both single-variant and gene-based association tests among five severity groups including asymptomatic, mild, moderate, severe, and critical ill patients after the correction of potential confounding factors. Pedigree analysis suggested a potential monogenic effect of loss of function variants in GOLGA3 and DPP7 for critically ill and asymptomatic disease demonstratio
Astrocytic TET2 expression is downregulated in human Alzheimer's disease brain tissue and correlates with cognitive decline severity
PURPOSE: Gastric dysmotility has been reported in patients with long-standing diabetes mellitus (DM). Some patients with DM are diagnosed as diabetes gastroparesis and have several upper gastrointestinal (GI) symptoms such as appetite loss and abdominal pain. This study aimed to identify the relationship between gastric motility and upper GI symptoms in patients with long-standing DM. METHOD: This study was conducted among 23 patients with DM and 15 healthy controls. All the patients with DM were receiving insulin treatment and had at least one history of incidence of diabetic nephropathy, retinopathy or neuropathy. Gastric motility was evaluated using electrogastrography (EGG) and gastric emptying using the 13C-acetic acid breath test. The most severe upper gastrointestinal symptoms were assessed in all patients. RESULTS: Compared to healthy controls, patients with long-standing DM showed a significantly lower percentage of normogastria at the postprandial state with a lower power rat
Overexpression of TET2 in reactive astrocytes promotes anti-inflammatory gene expression patterns and reduces neuronal damage in stroke models
A photonic microwave frequency divider that is capable to realise tunable high order frequency division, is presented. It is based on injecting an RF phase modulated optical signal into an off-the-shelf DFB laser operating at period-N state. Optical frequency components with a frequency separation of 1/N times the input RF signal frequency are generated by the DFB laser. An optical bandpass filter can be employed to select two optical frequency components to be detected by a photodetector to obtain a divide-by-N RF signal without harmonic components. The proposed frequency divider can be operated over a wide frequency range and has high reconfigurability as it is free of electrical components. Experimental results demonstrate the realisation of frequency division operation with a tunable 1/2 to 1/5 division ratio for different input RF signal frequencies of 8 to 20 GHz by adjusting the DFB laser forward bias current. Over 35 dB harmonic component suppression is demonstrated. A proof-of
The function and regulation of TET2 in innate immunity and inflammation.
TET2, a member of ten-eleven translocation (TET) family as α-ketoglutarate- and Fe2+-dependent dioxygenase catalyzing the iterative oxidation of 5-methylcytosine (5mC), has been widely recognized to be an important regulator for normal hematopoiesis especially myelopoiesis. Mutation and dysregulation of TET2 contribute to the development of multiple hematological malignancies. Recent studies reveal that TET2 also plays an important role in innate immune homeostasis by promoting DNA demethylation or independent of its enzymatic activity. Here, we focus on the functions of TET2 in the initiation and resolution of inflammation through epigenetic regulation and signaling network. In addition, we highlight regulation of TET2 at various molecular levels as well as the correlated inflammatory diseases, which will provide the insight to intervene in the pathological process caused by TET2 dysregulation.
RNA m(5)C oxidation by TET2 regulates chromatin state and leukaemogenesis.
Mutation of tet methylcytosine dioxygenase 2 (encoded by TET2) drives myeloid malignancy initiation and progression1-3. TET2 deficiency is known to cause a globally opened chromatin state and activation of genes contributing to aberrant haematopoietic stem cell self-renewal4,5. However, the open chromatin observed in TET2-deficient mouse embryonic stem cells, leukaemic cells and haematopoietic stem and progenitor cells5 is inconsistent with the designated role of DNA 5-methylcytosine oxidation of TET2. Here we show that chromatin-associated retrotransposon RNA 5-methylcytosine (m5C) can be recognized by the methyl-CpG-binding-domain protein MBD6, which guides deubiquitination of nearby monoubiquitinated Lys119 of histone H2A (H2AK119ub) to promote an open chromatin state. TET2 oxidizes m5C and antagonizes this MBD6-dependent H2AK119ub deubiquitination. TET2 depletion thereby leads to globally decreased H2AK119ub, more open chromatin and increased transcription in stem cells. TET2-mutan
TET2 guards against unchecked BATF3-induced CAR T cell expansion.
Further advances in cell engineering are needed to increase the efficacy of chimeric antigen receptor (CAR) and other T cell-based therapies1-5. As T cell differentiation and functional states are associated with distinct epigenetic profiles6,7, we hypothesized that epigenetic programming may provide a means to improve CAR T cell performance. Targeting the gene that encodes the epigenetic regulator ten-eleven translocation 2 (TET2)8 presents an interesting opportunity as its loss may enhance T cell memory9,10, albeit not cause malignancy9,11,12. Here we show that disruption of TET2 enhances T cell-mediated tumour rejection in leukaemia and prostate cancer models. However, loss of TET2 also enables antigen-independent CAR T cell clonal expansions that may eventually result in prominent systemic tissue infiltration. These clonal proliferations require biallelic TET2 disruption and sustained expression of the AP-1 factor BATF3 to drive a MYC-dependent proliferative program. This prolifera
TET2 suppresses vascular calcification by forming an inhibitory complex with HDAC1/2 and SNIP1 independent of demethylation.
Osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) has been recognized as the principal mechanism underlying vascular calcification (VC). Runt-related transcription factor 2 (RUNX2) in VSMCs plays a pivotal role because it constitutes an osteogenic transcription factor essential for bone formation. As a key DNA demethylation enzyme, ten-eleven translocation 2 (TET2) is crucial in maintaining the VSMC phenotype. However, whether TET2 involves in VC progression remains elusive. Here we identified a substantial downregulation of TET2 in calcified human and mouse arteries, as well as human primary VSMCs. In vitro gain- and loss-of-function experiments demonstrated that TET2 regulated VC. Subsequently, in vivo knockdown of TET2 significantly exacerbated VC in both vitamin D3- and adenine diet-induced chronic kidney disease (CKD) mouse models. Mechanistically, TET2 bound to and suppressed activity of the P2 promoter within the RUNX2 gene; however, an enzymatic loss-of-fu
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages.
Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2 resulted in a type I interferon response due to impaired mitochondrial DNA integrity and activation of cGAS signaling. DNMT3A and TET2 normally maintained mitochondrial DNA integrity by regulating the expression of transcription factor A mitochondria (TFAM) dependent on their interactions with RBPJ and ZNF143 at regulatory regions of the TFAM gene. These findings suggest that targeting the cGAS-type I IFN pathway may have therapeutic value in reducing risk of CVD in patients with DNMT3A or TET2
Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.
IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP) is linked to an increased incidence of cardiovascular and malignant diseases. OBJECTIVE: To determine whether CHIP is associated with cardiotoxic effects in patients with breast cancer receiving trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: Analyses of human cohorts with complementary animal experimentation were performed using a nationwide population-based cohort (UK Biobank), 1 tertiary referral center (Seoul National University Hospital [SNUH]), and a controlled laboratory setting. UK Biobank participants were enrolled between 2006 and 2010, and SNUH patients were enrolled from January 2004 to March 2024. Data were analyzed from March 2021 to February 2026. MAIN OUTCOME MEASURES: Incident heart failure (HF) in the UK Biobank cohort and trastuzumab-related cardiotoxic effects in the SNUH cohort were the main outcome measures. Trastuzumab-related cardiotoxic effects were defined using established clinical criteria (E
Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report.
Not available.
Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired Pure Red Cell Aplasia.
Immunosuppressive therapy (IST) is the standard treatment for acquired pure red cell aplasia (aPRCA), but predictors of treatment response and long-term prognosis remain unclear. The clinical significance of somatic mutations in aPRCA is not fully understood. We retrospectively analyzed 69 adult aPRCA patients who underwent targeted next-generation sequencing of 69 genes associated with clonal hematopoiesis and myeloid neoplasms. Somatic mutations, T-cell receptor (TCR) gene rearrangements, treatment response at 6 months, overall survival (OS), and progression-free survival (PFS) were evaluated. Somatic mutations were detected in 62.3% of patients, mainly in epigenetic regulators like DNMT3A and TET2. Although mutations did not predict 6-month response to IST, higher mutation burden was associated with worse treatment outcomes (p = 0.01). TP53 and DNMT3A mutations were linked to shorter OS and PFS. Survival worsened with increasing mutation numbers, while mutations in TET2, ASXL1, GATA
Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management.
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Despite its high mortality rate, IEC-HS remains underrecognized due to overlapping clinical and laboratory features with severe cytokine release syndrome (CRS), leading to delayed diagnosis and suboptimal management. This review systematically analyzes key strategies to distinguish IEC-HS from severe CRS in the literature. The analysis focuses on temporal patterns, such as the delayed onset of IEC-HS after CAR-T infusion. It also examines dynamic laboratory trends, including persistently elevated ferritin and lactate dehydrogenase levels and a slower decline in C-reactive protein (CRP). In addition, distinct cytokine profiles are discussed, such as prolonged interferon-gamma (IFN-γ) elevation and surges in chemokines and growth factors. We further identify high-risk factors for IEC-HS, including patient-specifi
Exosome-transmitted microRNA-323a-3p participated in the occurrence of Hirschsprung's disease.
BACKGROUND: Hirschsprung's disease (HSCR) is caused by defective enteric neural crest cell (ENCC) migration. Exosome-transmitted microRNAs are implicated in HSCR pathogenesis, but mechanisms remain unclear. METHODS: Plasma exosomes and colon tissues were collected from HSCR patients and controls. We assessed the effects of exosomal miR-323a-3p on the proliferation and migration of immortalized ENCC-derived neural cell line (iENC) in vitro using CCK-8, EdU and Transwell assays, and its impact on ENCC migration in vivo using a zebrafish model. RESULTS: Exosomal miR-323a-3p was significantly upregulated in the plasma of HSCR and exhibited prospective diagnostic relevance (AUC = 0.7269, p = 0.0043). Exosomal miR-323a-3p was taken up by iENCs and suppressed their proliferation and migration. TET2 was identified as a potential miR-323a-3p target. TET2 was downregulated in HSCR aganglionic tissues, and its knockdown inhibited iENC proliferation and migration. In the zebrafish model, exosomal
Demonstrates epigenetic therapy effects in disease management, suggesting potential for TET2-related interventions.
1. Front Pharmacol. 2026 Feb 24;17:1775173. doi: 10.3389/fphar.2026.1775173. eCollection 2026. Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects. Yu Y(1)(2), Tang...
Directly investigates TET2-NF-κB inflammation mechanisms in microglia, providing mechanistic evidence for neurological TET2 interactions.
1. Food Chem Toxicol. 2026 Mar 6;212:116055. doi: 10.1016/j.fct.2026.116055. Online ahead of print. Food-grade TiO(2)/TDCPP Co-exposure disrupts ACOD1/itaconate axis and is associated with...
Explores TET1 deficiency and inflammatory signaling, indicating broader relevance of TET family enzymes in inflammatory processes.
1. Inflamm Res. 2026 Mar 27;75(1):72. doi: 10.1007/s00011-026-02228-3. TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn's disease. Perez RK(1), Paul R(2), Kumar...
Specifically examines TET2-dependent epigenetic regulation, demonstrating broader relevance of enzyme in disease pathogenesis.
1. Cell Mol Life Sci. 2026 Mar 11;83(1):148. doi: 10.1007/s00018-026-06134-z. Tet methylcytosine dioxygenase 2(TET2)-dependent epigenetic regulation in the pathogenesis of polycystic ovary syndrome.
One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.
Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma.
Clonal Hematopoiesis and Risk of Stroke: Evidence From Over 800 000 Individuals Across 3 Cohorts.
Evidence against (7)
Programmable epigenetic editing tools face major delivery and efficiency challenges for in vivo CNS applications
Experimental data showed that high-speed microsprays can effectively disrupt biofilms on their support substratum, producing a variety of dynamic reactions such as elongation, displacement, ripple formation, and fluidization. However, the mechanics underlying the impact of high-speed turbulent flows on biofilm structure is complex under such extreme conditions, since direct measurements of viscosity at these high shear rates are not possible using dynamic testing instruments. Here, we used computational fluid dynamics simulations to assess the complex fluid interactions of ripple patterning produced by high-speed turbulent air jets impacting perpendicular to the surface of Streptococcus mutans biofilms, a dental pathogen causing caries, captured by high-speed imaging. The numerical model involved a two-phase flow of air over a non-Newtonian biofilm, whose viscosity as a function of shear rate was estimated using the Herschel-Bulkley model. The simulation suggested that inertial, shear,
Epigenetic erasure may remove protective methylation marks alongside pathological ones
Sterols are essential eukaryotic lipids that are required for a variety of physiological roles. The diagenetic products of sterol lipids, sterane hydrocarbons, are preserved in ancient sedimentary rocks and are utilized as geological biomarkers, indicating the presence of both eukaryotes and oxic environments throughout Earth's history. However, a few bacterial species are also known to produce sterols, bringing into question the significance of bacterial sterol synthesis for our interpretation of sterane biomarkers. Recent studies suggest that bacterial sterol synthesis may be distinct from what is observed in eukaryotes. In particular, phylogenomic analyses of sterol-producing bacteria have failed to identify homologs of several key eukaryotic sterol synthesis enzymes, most notably those required for demethylation at the C-4 position. In this study, we identified two genes of previously unknown function in the aerobic methanotrophic γ-Proteobacterium Methylococcus capsulatus that enc
TET2 overactivation leads to genome-wide hypomethylation and increased chromosomal instability in neural stem cells
Gamification has become a significant direction in designing technologies, services, products, organizational structures, and any human activities towards being more game-like and consequently being more engaging and motivating. Albeit its success, research indicates that personal differences exist with regards to susceptibility to gamification at large as well as to different types of gamification designs. As a response, models and measurement instruments of user types when it comes to gamification have been developed. One of the most discussed related instruments is the Hexad user types scale. However, there has been paucity of research related to the validity and reliability of the Hexad instrument in general but also of its different formulations and language versions. To face this gap, our study focused on analyzing the psychometric properties of the Hexad scale in Brazilian Portuguese by conducting two confirmatory factor analyses and two multi-group confirmatory factor analyses.
Excessive TET-mediated demethylation disrupts normal astrocyte differentiation programs and impairs synaptic support functions
Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs
TET enzyme modulators show poor blood-brain barrier penetration and require invasive delivery methods for therapeutic efficacy
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a rapid accumulation of amyloid β (Aβ) protein in the hippocampus, which impairs synaptic structures and neuronal signal transmission, induces neuronal loss, and diminishes memory and cognitive functions. The present study investigated the impact of neuregulin 1 (NRG1)-ErbB4 signaling on the impairment of neural networks underlying hippocampal long-term potentiation (LTP) in 5xFAD mice, a model of AD with greater symptom severity than that of TG2576 mice. Specifically, we observed parvalbumin (PV)-containing hippocampal interneurons, the effect of NRG1 on hippocampal LTP, and the functioning of learning and memory. We found a significant decrease in the number of PV interneurons in 11-month-old 5xFAD mice. Moreover, synaptic transmission in the 5xFAD mice decreased at 6 months of age. The 11-month-old transgenic AD mice showed fewer inhibitory PV neurons and impaired NRG1-ErbB4 signaling than did wild-type mice,
TET2 in epigenetic control of immune cells: Implications for inflammatory responses and age-related pathologies.
Ten-eleven translocation 2 (TET2) is an epigenetic modifier whose canonical activity leads to the removal of cytosine methylation in the genome, which in essence results in the activation of gene expression. This function is particularly well described in the context of hematopoiesis and its alterations that lead to leukemia. However, in recent years, it has become evident that the noncanonical functions of TET2 also play a vital role in its activity. Rather than depending on its catalytic activity, these functions arise from TET2 interactions with other epigenetic modifiers. This review summarizes the structure, regulation, and functions of TET2 in immune cells. We describe how TET2 controls gene expression at both the DNA and RNA levels. In addition, we discuss the role of TET2 in hematopoietic stem cell fate and in clonal hematopoiesis of indeterminate potential. Finally, we highlight the impact of TET2 mutations on age-related inflammatory diseases, including cardiovascular and neu